---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-096243"
form_type: "8-K"
ticker: "TARA"
cik: "0001359931"
company_name: "Protara Therapeutics, Inc."
filed_at: "2024-11-12T23:59:59+00:00"
generated_at: "2026-05-30T01:40:12.417674+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Protara Therapeutics reports Q3 2024 net loss of $11.2M; cash $81.5M; pipeline on track

## Summary
- Net loss $11.2M ($0.50 per share) vs $9.9M ($0.87) in Q3 2023; no revenue.
- Cash, equivalents, and investments $81.5M as of Sept 30; sufficient to fund operations into 2026.
- R&D expenses $8.1M; G&A $4.3M; stock-based comp $0.9M.
- On track to report interim 6-month data from TARA-002 in NMIBC ADVANCED-2 trial in 4Q 2024.
- FDA Fast Track granted for IV Choline Chloride; THRIVE-3 first patient dosing expected in 1Q 2025.

## SEC filing metadata
- accession: 0001213900-24-096243
- form_type: 8-K
- ticker: TARA
- cik: 0001359931
- company_name: Protara Therapeutics, Inc.
- filed_at: 2024-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1359931/000121390024096243/0001213900-24-096243-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1359931/000121390024096243/ea0219258-8k_protara.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-096243
- JSON: https://secwatch.observer/filing/0001213900-24-096243.json
- Plain text: https://secwatch.observer/filing/0001213900-24-096243.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.